Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

This phase II, open-label, multicenter study evaluates zanubrutinib in patients aged 80 years and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who require treatment. CLL and SLL are slow-growing blood cancers that mainly affect older adults. Although zanubrutinib is an effective treatment, taking it continuously at the full dose may increase the risk of side effects over time, particularly in elderly patients. The study aims to assess whether a planned reduction in the dose of zanubrutinib after an initial period of treatment can maintain disease control while improving long-term tolerability.

NCT Number	NCT07739459
Lead Sponsor	The Lymphoma Academic Research Organisation Collaborators: Lymphoma Study Association, BeOne Medicines
Conditions	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment	95 participants
Start Date	2026-12
Primary Completion	2029-04 (estimated)
Study Completion	2032-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-31